PDS Biotechnology
PDSB
55 hedge funds and large institutions have $166M invested in PDS Biotechnology in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 5 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
7% more capital invested
Capital invested by funds: $156M → $166M (+$10.2M)
2% more funds holding
Funds holding: 54 → 55 (+1)
0.04% more ownership
Funds ownership: 2.47% → 2.51% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$5.47M |
| 2 |
JP Morgan Chase
New York
|
+$2.71M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.9M |
| 4 |
Renaissance Technologies
New York
|
+$1.16M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
-$6.76M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.6M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.33M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$573K |
| 5 |
Janus Henderson Group
London,
|
-$451K |
PDSB Hedge Fund Activity: Q3 2017 in Review
55 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2017, worth a combined $166M — up 6.5% from $156M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PDSB positions and 5 closed out — a net gain of 1 holder — while 23 added to existing stakes and 14 trimmed.
The largest buyer was Franklin Resources, adding an estimated $5.47M. The largest seller was VHCP Management II, cutting an estimated $6.76M.
- 55 institutional investors held PDS Biotechnology (PDSB) as of Q3 2017, up from 54 in Q2 2017.
- Funds reported $166M of PDS Biotechnology stock for Q3 2017, up 6.5% quarter-over-quarter.
- 6 funds opened new PDS Biotechnology positions in Q3 2017 and 5 closed out, a net change of +1 holder.
- The largest PDS Biotechnology buyer in Q3 2017 was Franklin Resources, an estimated $5.47M added.
- The largest PDS Biotechnology seller in Q3 2017 was VHCP Management II, an estimated $6.76M sold.
Based on aggregated 13F filings for Q3 2017.